Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection
Posted: 23 April 2020 | Dr Rosa Tordera (University of Navarra), Maria Cortes (University of Navarra) | No comments yet
Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
Click here to download the research.
With regular news updates and feature articles, our COVID-19 hub has everything you need to keep up to date with R&D during the pandemic. Click below to visit:
Related topics
Drug Targets, Enzymes, Research & Development
Related conditions
Coronavirus, Covid-19
